Collection, cryostorage, transplantation and disposal of hematopoietic stem cell products

High-dose chemotherapy (HD-CHT) followed by autologous blood stem cell transplantation (ABSCT) represents a standard therapy for a variety of malignant and non-malignant diseases, including leukemia, lymphoid malignancies, multiple myeloma (MM), solid tumors (e.g., germ cell tumors, sarcoma), amyloid light chain (AL) amyloidosis and autoimmune disorders.1-5 Peripheral blood stem cells (PBSCs) have become the most widely used source for hematopoietic stem cells in this setting.6,7 Considering the difficulties of collecting an additional PBSC graft after the initial myeloablative HD-CHT and ABSCT, many centers routinely collect and store two or even more PBSC harvests in order to ensure a tandem and/or salvage ABSCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research